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Starting question: “Can catalytic antibodies (and if they do, how) be considered a paradigmatic example of how 
closely basic research is intertwined with knowledge of pathology / design of new therapeutic strategies?” 
Aim: to find an example of catalytic antibody to answer the question. Four areas of interest (Methods of generation, 
Reaction mechanisms, Natural occurrence in pathology and Versatility of applications) were defined to guide 
research and achieve an overall vision of the field.  
 
The PubMed database was searched using the words “catalytic antibody”, initially, and “aldolase 38C2”, once the 
example of catalytic antibody had been selected. In both cases, reviews were chosen based on publication date and 
quality of the journal. Later, relevant original papers were found thanks to the knowledge acquired and also by using 
the ISI Web of Knowledge.  
 
Catalytic antibodies, sometimes also referred to as “abzymes”, are antibodies that possess catalytic activity. The 
concept of catalytic antibody is based on Pauling’s “transition state theory”, according to which enzymes catalyze a 
given reaction by stabilizing the transition state. In the 1980s, Richard Lerner and colleagues showed that by using 
transition state analogues as immunogens, it is feasible to trigger enzymatic activity in antibodies. Later on, 
alternative approaches for generation of catalytic antibodies have been developed, and naturally occurring catalytic 
antibodies have been found in the context of many diseases, displaying both pathologic and beneficial roles.  
• Mimics class I natural aldolases -> bears a reactive lysine 
 
• Produced by “reactive immunization”: the immunogen is actually a 
chemical reaction -> enamine formation between the desired lysine and 
a β-1,3 diketone hapten (Fig.1) 
 
• Has broad scope specificity and Kcat/kM comparable to natural aldolases 
 
• Reactive lysine is found in framework region 3 of the variable domain of 
the heavy chain 
• Structure of related 33F12 antibody (92% identity) -> LysH93 lies at the bottom of 
a 11 Å deep cleft (Fig.2) 
 
- Without establishing hydrogen bonds 
- In Van der Waals contact with several hydrophobic residues  
Figure 1. Lysine trapping by hapten. 
Taken from [1] 
Figure 2. 32F12 active site. The enamine 
conjugate between LysH93 and hapten from 
Scheme 1 can be seen. Taken from [1]  
↓pKa -> required for 
mechanism 
 
v Required  for feasibility of clinical trials  
All mouse 38C2 (m38C2) CDR residues (from light 
chain and heavy chain) and 12 selected framework 
region (FR) residues were engrafted into a combination 
of human V and J genes for the light and heavy chain 
variable domains -> fusion to constant domains -> Fab
fragment -> IgG  
 
Selection of FR residues was based on 33F12 structure 
(see Fig.2): 
-Catalytic lysine
-6 residues within 5A of LysH93 ε-amino group 
-5 residues that line the substrate binding pocket 
 
Humanized 38C2 (h38C2) had similar Kcat and kM and 
preferred tertiary aldols compared to secondary aldols 
like m38C2 does. 
Antibody-Directed Abzyme Prodrug Therapy 
(ADAPT) 
  
Bifunctional antibodies 
  
Prodrugs contain a tertiary aldol and an oxa-
Michael motif -> retro-aldol-retro-Michael tandem 
reaction by 38C2 releases free drug: 
 
  
 
 
 
This strategy achieves: 
-Local targeted release of drug -> less side effects  
-Specificity: hydrophobic prodrug is not a substrate 
for endogenous aldolases 
-Less immunogenicity than an enzyme 
 
Chemically programmed antibodies (cpAbs) 
  
• “Targeting agents” (TA) are attached to 38C2 
through the reactive lysine LysH93 via: 
 - Diketone compound 
- Vinylketone compound 
- βlactam group 
 
• A linker is required to allow the TA to be 
exposed outside the 11 Å-deep active site  
 
• Benefits: 
-Blood half-life of the TA is extended to that of 
an antibody  
-Effector functions of the antibody’s Fc can 
contribute to the therapeutic action  
 
 
v Catalytic activity is lost! 
*This is used to verify successful conjugation   
  
 
 
The conjugation strategy is based on the reactivity of a β-lactam group with LysH93:  
  ADAPT therapy 
 
 
Catalytic antibody aldolase 38C2 is an excellent example of interdisciplinary transfer of knowledge because:  
 
•. Detailed mechanistic information was used for the hapten design and trapping of the reactive lysine 
•. Structural information was the basis for the successful humanization process 
•. In spite of catalytic activity being lost, use of 38C2 as a chemically programmed antibody is a very promising and versatile therapeutic strategy 
that has reached clinical trials 
1. Introduction 
2. Aims and methods 
3. Characteristics of 38C2 
4. Humanization process 5. 38C2-based therapeutic strategies 
6. CpAbs for infectious disease treatment  
Figure 3. 3D representation of the engraftment of mouse 
38C2 active site to human 38C2 generated by PyMOL® 
The Fab fragment of 33F12 is shown (PDB accession 
number 3FO9) in complex with a diketone hapten (black 
sticks). Grey ribbons correspond to constant domains and 
residues of variable domains that were not conserved from 
mouse in the humanization process, and are not shown in 
the close-up on the right. See text for colour legend. 
Influenza 
 
• Zanamivir is a neuraminidase (NA) inhibitor 
-> blocks de novo virion release 
• Half-life of 38C2-zanamivir cpAb was 120 
hours (vs. 10 minutes for zanamivir)  
         *2 doses / day -> 1/2 doses / month 
  
v There is large antigenic variation on the 
surface of NA (for immune evasion). The 
active site of NA is less tolerant to 
mutations and can be reached by a small 
compound such as Zanamivir -> the cpAb 
approach combines the positive features 
of zanamivir and the antibody scaffold 
 
 
HIV-1 
 
• Entrance of virions is mediated by gp120 antigen, which 
binds the CD4 receptor and CCR5 coreceptor 
 
• CpAb of BMS-488043 (anti-gp120) has reduced but 
significant neutralization activity 
 
• Maraviroc blocks CCR5. 
         - CpAb retains full activity for 10 days 
         - CpAb has broad spectra like Maraviroc (see Figure 7) 
         - Unknown toxicity of cpAb  
 
 
 
 
 
Figure 6. Taken 
from [3]   
target-specific antibody 
38C2 for prodrug activation 
 
8. Conclusions 
Figure 5. ADAPT and cpAbs modes of action 
On the left, green corresponds to the target-specific arm and orange 
to the 38C2 catalytic arm of a bifunctional antibody for ADAPT. 
On the right, orange represents 38C2 and purple a targeting agent.  
Membrane targets are shown in blue.     
7. 38C2-based cancer treatment 
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CovX-Body  Mechanism of action Clinical trials (phase; state) 
CVX-060 Neutralize angiopoietin-2 NCT00879684 (phase I; completed)  
NCT00982657 (phase I/II; completed, no results available)  
     *CVX-060 + sunitinib (tyrosine kinase inhibitor)  
NCT01441414 (phase II; terminated due to unexpected arterial and 
venous thrombotic events) 
     *CVX-060 + axitinib (tyrosine kinase inhibitor) 
CVX-045 Mimic thrombospondin-1 NCT00879554 (phase I; completed)  
CVX-241 Neutralize angiopoietin-2 and VEGF NCT01004822 (phase I; terminated due to poor pharmacokinetics, 
no safety concerns)  
CpAbs 
 
Integrin-targeted: 
• TA: small integrin inhibitors 
 
• Integrins are key regulators of angiogenesis 
 
• CpAbs targeting integrins αvβ3 and αvβ5 can inhibit 
tumour growth by acting upon: 
          - tumour cells. Figure 11: neoangiogenesis is not  
            required for tumour development in the lung  
          - endothelial cells 
          - both  
 
CovX-2000 platform 
• Developed by Pfizer using h38C2 
 
• TA are attached using an azetidinone linker (β-lactam 
approach) 
 
• In phase I studies, all CovX-bodies (see Table 1) were 
well tolerated and allowed once a week dosing 
 
v However, these cpAbs have been discontinued from 
Pfizer pipeline in 2014 -> uncertainty regarding further 
clinical trials  
 
 
Figure 7. Blood half-life of zanamivir 
derived cpAb. Adapted from [3] 
Figure 8. 
Neutralization 
assays using 
Maraviroc and 
corresponding 
cpAb. 
92RW belongs 
to clade A, JR-
FL and YU-2 to 
clade B and 
MGC26 to clade 
C.  
Adapted from [4] 
Prodrugs substrate for 38C2 have been generated from:  
-   Doxorubicin and duocarmycin (DNA intercalating agents) 
- Etoposide and camptothecin (topoisomerase inhibitors) 
- Enediynes (DNA-cleaving agents) 
 
There is one in vivo study in mice with NXS2 cell line 
primary neuroblastomas: 
• m38C2 (intratumoural)  + etoposide prodrug (systemical) 
at 1250 mg/kg body weight -> 75% ↓ of tumor growth  
• No side effects 
 
 
v The targeting arm of the bifunctional designed construct
remains unexplored -> results have to be mainly 
attributed to the Enhanced Permeation Effect 
v A variant of ADAPT was proposed: chemically labelled 
antibodies -> 38C2 + TA NOT attached to reactive lysine 
Active site  
entrance 
Figure 4. 38C2-catalysed prodrug activation. Adapted from [2] 
Figure 9. Taken from [5] 
Figure 11. Lung metastatic foci in SCID mice 
inoculated with human melanoma M21 cells. 
LM609 binds human αvβ3 integrin. Doses 
correspond to μg / injection. Taken from [7] 
Table 1. Summary of clinical trials with CovX-Bodies for cancer treatment. Adapted from [8]   
Figure 10. Taken from [6] 
